Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of the IGF-1R Antibody AMG 479 in Combination With Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer (The RAP Trial)

NCT01061788 is registered in ClinicalTrials.gov with Jeffrey Clarke as lead sponsor.

NCT NCT01061788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01061788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of the IGF-1R Antibody AMG 479 in Combination With Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer (The RAP Trial)
Lead sponsor
Jeffrey Clarke
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2010
Completion date
December 19, 2018
Enrollment
43 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, non-small cell lung cancer